Table 3 Univariable and multivariable analysis of baseline prognostic factors of overall survival
Survival | Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
N , median (Q3-Q1) | HR, 95% CI | P -value | HR, 95% CI | P -value | |
Age | |||||
<70 years | 160, 26.2 (43–14.3) | Reference | Reference | ||
⩾70 years | 98, 22.6 (40.3–9.2) | 1.33, (0.98–1.81) | 0.068 | 1.19, (0.82–1.72) | 0.366 |
Gender | |||||
Male | 145, 24 (38.6–11.3) | 1.47, (1.07–2.00) | 0.016 | 1.38, (0.95–2.02) | 0.095 |
Female | 113, 26.1 (46.9–14.3) | Reference | Reference | ||
Performance status | |||||
0 | 131, 27.2 (44–14.7) | Reference | Reference | ||
1 | 127, 24.5 (40.3–10) | 1.17, (0.86–1.59) | 0.320 | 0.96, (0.67–1.39) | 0.833 |
Tumour length | |||||
<2 cm | 56, 30.7 (46.4–12.1) | Reference | Reference | ||
2–4 cm | 85, 30.3 (46.9–14.8) | 1.00, (0.63–1.57) | 0.992 | 1.16, (0.70–1.89) | 0.568 |
4–6 cm | 55, 24.9 (42.4–11.5) | 1.48, (0.93–2.36) | 0.102 | 1.40, (0.79–2.47) | 0.250 |
6–8 cm | 62, 18.2 (35.9–10) | 1.87, (1.18–2.96) | 0.008 | 1.81, (1.05–3.12) | 0.034 |
Stage | |||||
I+II | 103, 35.9 (46.6–15.3) | Reference | Reference | ||
III | 155, 23.2 (37–11.3) | 1.66, (1.20–2.30) | 0.002 | 1.58, (1.05–2.38) | 0.027 |
Tumour type | |||||
Squamous cell | 188, 25.4 (43.3–13.6) | Reference | Reference | ||
Adenocarcinoma | 70, 23.2 (39.1–10.2) | 1.28, (0.92–1.78) | 0.144 | 0.97, (0.62–1.52) | 0.907 |
Reason for no surgery | |||||
Patient choice | 97, 26.7 (46.6–14.7) | Reference | Reference | ||
Comorbidity | 36, 31.6 (42.7–11.1) | 1.24, (0.79–1.94) | 0.350 | 0.93, (0.51–1.70) | 0.817 |
Local extent | 122, 24 (40.6–11.5) | 1.20, (0.86–1.69) | 0.285 | 0.87, (0.58–1.29) | 0.478 |
Treatment arm | |||||
dCRT only | 129, 23.3 (39.4–10.2) | Reference | |||
dCRT + cetuximab | 129, 27.8 (46–14.8) | 1.27, (0.94–1.71) | 0.125 | 0.82, (0.49–1.37) | 0.440 |
Full radiation protocol dose | |||||
Yes | 217, 30.1 (46–14.9) | Reference | Reference | ||
No | 41, 8.2 (20.8–2.9) | 3.46, (2.36–5.07) | <0.001 | 2.92, (1.49–5.75) | 0.002 |
% of full cisplatin protocol dose | |||||
⩾95% | 106, 35.2 (46.9–16.9) | Reference | Reference | ||
⩾75–<95% | 76, 29 (44.3–15.3) | 1.29, (0.88–1.90) | 0.184 | 1.11, (0.70–1.75) | 0.672 |
⩾50–<75% | 41, 18.4 (36–12.5) | 2.20, (1.44–3.38) | <0.001 | 1.76, (1.00–3.13) | 0.051 |
<50% | 35, 10.2 (24.7–5.9) | 3.17, (2.00, 5.03) | <0.001 | 1.80, (0.86–3.76) | 0.118 |
% of full capecitabine protocol dose | |||||
⩾95% | 82, 32.8 (45.3–14.9) | Reference | Reference | ||
⩾75–<95% | 90, 28.1 (45.9–14.8) | 1.07, (0.73–1.59) | 0.719 | 0.99, (0.62–1.58) | 0.956 |
⩾50–<75% | 52, 22.5 (43.3–7.7) | 1.58, (1.03–2.41) | 0.035 | 0.97, (0.54–1.73) | 0.907 |
<50% | 34, 15.6 (23.2–5.9) | 2.34, (1.46–3.76) | <0.001 | 0.73, (0.32–1.69) | 0.465 |
NRI | |||||
⩾100 | 217, 28 (45.9–14.2) | Reference | Reference | ||
<100 | 41, 15.6 (24.5–8) | 2.26, (1.54–3.30) | <0.001 | 12.45, (5.24–29.6) | <0.001 |
Nutritional intervention | |||||
None | 114, 29.2 (46.8–12.8) | Reference | |||
Dietary advice alone | 44, 29 (44.6–15.7) | 1.05, (0.67–1.63) | 0.835 | 1.18, (0.59–2.39) | 0.638 |
Oral supplements | 74, 23.4 (35.8–10.9) | 1.49, (1.04–2.15) | 0.030 | 1.00, (0.54–1.85) | 0.992 |
Major intervention | 25, 23.7 (40.3–10) | 1.20, (0.69–2.08) | 0.525 | 0.53, (0.19–1.50) | 0.232 |
Nutritional intervention in the CRT + cetuximab group | |||||
None | Reference | ||||
Dietary advice alone | 1.19, (0.45–3.15) | 0.720 | |||
Oral supplements | 1.94, (0.89–4.20) | 0.093 | |||
Major intervention | 4.69, (1.40–15.7) | 0.012 | |||
Nutritional intervention in those with a baseline NRI<100 | |||||
None | Reference | ||||
Dietary advice alone | 0.12, (0.03–0.51) | 0.004 | |||
Oral supplements | 0.13, (0.04–0.39) | <0.001 | |||
Major intervention | 0.13, (0.03–0.50) | 0.003 | |||
